These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
87 related articles for article (PubMed ID: 17284993)
21. [Chronic renal failure after heart, lung, liver, or intestine transplantation]. Kes P; Basić-Jukić N; Jurić I Acta Med Croatica; 2008; 62 Suppl 1():60-8. PubMed ID: 18578334 [TBL] [Abstract][Full Text] [Related]
22. Repeated daclizumab administration to delay the introduction of calcineurin inhibitors in heart transplant patients with postoperative renal dysfunction. Sánchez Lázaro IJ; Almenar Bonet L; Martínez Dolz L; Buendía Fuentes F; Navarro Manchón J; Agüero Ramón-Llin J; Vicente Sánchez JL; Salvador Sanz A Rev Esp Cardiol; 2011 Mar; 64(3):237-9. PubMed ID: 21310520 [TBL] [Abstract][Full Text] [Related]
23. Long-term renal function in pediatric liver and heart recipients. Alonso EM Pediatr Transplant; 2004 Aug; 8(4):381-5. PubMed ID: 15265166 [TBL] [Abstract][Full Text] [Related]
24. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease. Berger AK; Duval S; Manske C; Vazquez G; Barber C; Miller L; Luepker RV Am Heart J; 2007 Jun; 153(6):1064-73. PubMed ID: 17540211 [TBL] [Abstract][Full Text] [Related]
25. Chronic allograft dysfunction: can we use mammalian target of rapamycin inhibitors to replace calcineurin inhibitors to preserve graft function? Wali RK; Weir MR Curr Opin Organ Transplant; 2008 Dec; 13(6):614-21. PubMed ID: 19060552 [TBL] [Abstract][Full Text] [Related]
26. Long-term calcineurin inhibitor "holiday" using daclizumab in a heart transplant patient with acute renal dysfunction. Potter B; Giannetti N; Cecere R; Cantarovich M J Heart Lung Transplant; 2005 Aug; 24(8):1126-8. PubMed ID: 16102455 [No Abstract] [Full Text] [Related]
27. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure. Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651 [TBL] [Abstract][Full Text] [Related]
28. Does concurrent renin-angiotensin-aldosterone blockade in (older) chronic kidney disease patients play a role in the acute renal failure epidemic in US hospitalized patients?--Three cases of severe acute renal failure encountered in a northwestern Wisconsin Nephrology practice. Onuigbo MA Hemodial Int; 2009 Oct; 13 Suppl 1():S24-9. PubMed ID: 19775421 [TBL] [Abstract][Full Text] [Related]
29. Evaluation of the efficacy and safety of the conversion from a calcineurin inhibitor to an everolimus-based therapy in maintenance renal transplant patients. Sánchez Fructuoso A; Ruiz San Millán JC; Calvo N; Rodrigo E; Moreno MA; Cotorruelo J; Conesa J; Gómez-Alamillo C; Arias M; Barrientos A Transplant Proc; 2007 Sep; 39(7):2148-50. PubMed ID: 17889120 [TBL] [Abstract][Full Text] [Related]
30. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function. Watson CJ; Gimson AE; Alexander GJ; Allison ME; Gibbs P; Smith JC; Palmer CR; Bradley JA Liver Transpl; 2007 Dec; 13(12):1694-702. PubMed ID: 18044728 [TBL] [Abstract][Full Text] [Related]
31. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients. Raichlin E; Khalpey Z; Kremers W; Frantz RP; Rodeheffer RJ; Clavell AL; Edwards BS; Kushwaha SS Transplantation; 2007 Aug; 84(4):467-74. PubMed ID: 17713429 [TBL] [Abstract][Full Text] [Related]
32. Cancers after renal transplantation. Wong G; Chapman JR Transplant Rev (Orlando); 2008 Apr; 22(2):141-9. PubMed ID: 18631867 [TBL] [Abstract][Full Text] [Related]
33. Sirolimus-based immunosuppression after cardiac transplantation: predictors of recovery from calcineurin inhibitor-induced renal dysfunction. Gustafsson F; Ross HJ; Delgado MS; Bernabeo G; Delgado DH J Heart Lung Transplant; 2007 Oct; 26(10):998-1003. PubMed ID: 17919619 [TBL] [Abstract][Full Text] [Related]
34. Effects of sirolimus vs. calcineurin inhibitors on renal dysfunction after orthotopic liver transplantation. Campbell MS; Rai J; Kozin E; Bloom RD; Markmann JF; Olthoff KM; Shaked A; Rajender Reddy K Clin Transplant; 2007; 21(3):377-84. PubMed ID: 17488388 [TBL] [Abstract][Full Text] [Related]
35. Risk factors for the development and progression of renal diseases in disadvantaged populations: role of the renin-angiotensin system blockade. Maione A; Strippoli GF Ethn Dis; 2009; 19(1 Suppl 1):S1-86-9. PubMed ID: 19484883 [TBL] [Abstract][Full Text] [Related]
36. Quantitative appraisal of treatment options for IgA nephropathy. Ballardie FW J Am Soc Nephrol; 2007 Nov; 18(11):2806-9. PubMed ID: 17942959 [TBL] [Abstract][Full Text] [Related]
37. New opportunities in cardiovascular patient management: a survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Weber MA Am J Cardiol; 2007 Aug; 100(3A):45J-52J. PubMed ID: 17666198 [TBL] [Abstract][Full Text] [Related]
38. The challenge of renal function in heart transplant children. Di Filippo S; Cochat P; Bozio A Pediatr Nephrol; 2007 Mar; 22(3):333-42. PubMed ID: 16932899 [TBL] [Abstract][Full Text] [Related]